viewCellmid Limited

Cellmid's Maria Halasz buys shares on market

Maria Halasz has increased her shareholding through buying on market.

Cellmid shares are up 15% in 2017 trading at $0.03

Cellmid (ASX:CDY) has had its managing director and CEO, Maria Halasz, purchase 400,000 shares on market recently.

This takes Halasz’s Total direct and indirect holding to 27.3 million shares.

Total consideration for the 400,000 shares purchased amounted to $11,600 for an average price of $0.029.

Cellmid has two business segments, consumer health and its midkine (MK) portfolio.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

Cellmid aims to follow in the footsteps of FGF5 by commercialising its MK portfolio.

Cellmid recorded a 79% increase in December quarter hair loss product sales compared with the prior December quarter and will enter 2017 with a healthy $5.3 million in cash.

Quick facts: Cellmid Limited


Price: 0.054 AUD

Market Cap: $10.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Cellmid expects to see strong revenue growth out of China ahead of...

Cellmid Ltd’s (ASX:CDY) Maria Halasz speaks to Proactive's Andrew Scott following the news it's received the first order from Ourui Health Management Limited (OHM) for the sale of its Japanese, Ju-Ju® and Lexilis® branded, anti-ageing hair and skincare products in China. The first order of...

on 27/1/21

2 min read